Toni Choueiri

Academic History

Toni Choueiri, MD, is the Director of the Lank Center for Genitourinary (GU) Oncology and Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute, Boston, MA. He is the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School and Co-Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center. He previously served as President of the Medical Staff at Dana-Farber Cancer Institute.

Prof. Choueiri earned his medical degree from Saint Joseph University Faculty of Medicine, Beirut, Lebanon. He later completed his residency in Internal Medicine and a Fellowship in Hematology and Medical Oncology at the Cleveland Clinic Foundation, Cleveland, OH. He is board certified in Internal Medicine and Medical Oncology.

Speaking on biomarker-based systemic therapies in GU malignancies

Prof. Choueiri is an internationally recognized clinician-scientist whose work has shaped the field of genitourinary oncology, particularly renal cell carcinoma (RCC). His research focuses on the biology of RCC, including genomic and tumor microenvironment factors driving treatment response and resistance. He has led pivotal clinical trials resulting in the FDA approval of multiple therapies for metastatic RCC, and has significantly contributed to the development of biomarker-based treatment strategies, including the International Metastatic RCC Database Consortium (IMDC) risk model. His work also addresses rare RCC subtypes, such as papillary, translocation, and sarcomatoid variants, through translational studies and rationally designed trials. A top 1% highly cited researcher in clinical medicine, Prof. Choueiri continues to advance precision medicine in GU malignancies.